Evidence map›Paper›PMID 29116108›Full record

ArticleScientific reports2017

Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide.

Pablo Scodeller, Lorena Simón-Gracia, Sergei Kopanchuk, Allan Tobi, Kalle Kilk, Pille Säälik, Kaarel Kurm, Mario Leonardo Squadrito, Venkata Ramana Kotamraju, Ago Rinken and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 174 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Pablo ScodellerLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia. pablo.david.scodeller@ut.ee.
Lorena Simón-GraciaLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
Sergei KopanchukInstitute of Chemistry, University of Tartu, Ravila 14, Tartu, 50411, Estonia.
Allan TobiLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
Kalle KilkDepartment of Biochemistry, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
Pille SäälikLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
Kaarel KurmLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
Mario Leonardo SquadritoSchool of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Swiss Federal Institute of Technology, Lausanne, CH-1015, Lausanne, Switzerland.
Venkata Ramana KotamrajuCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N, Torrey Pines Road, La Jolla, 92097, California, USA.
Ago RinkenInstitute of Chemistry, University of Tartu, Ravila 14, Tartu, 50411, Estonia.
Michele De PalmaSchool of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Swiss Federal Institute of Technology, Lausanne, CH-1015, Lausanne, Switzerland.
Erkki RuoslahtiCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N, Torrey Pines Road, La Jolla, 92097, California, USA.
Tambet TeesaluLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia. tambet.teesalu@ut.ee.
University of Tartu · EEÉcole Polytechnique Fédérale de Lausanne · CHCancer Research Center · USDiscovery Institute · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
A nanosystem for tumor treatment and imagingR01CA188883 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2014 to 2018
$2.0M
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA188883Wellcome TrustWellcome Trust WT095077MA
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) expressing the multi-ligand endocytic receptor mannose receptor (CD206/MRC1) contribute to tumor immunosuppression, angiogenesis, metastasis, and relapse. Here, we describe a peptide that selectively targets MRC1-expressing TAMs (MEMs). We performed in vivo peptide phage display screens in mice bearing 4T1 metastatic breast tumors to identify peptides that target peritoneal macrophages. Deep sequencing of the peptide-encoding inserts in the selected phage pool revealed enrichment of the peptide CSPGAKVRC (codenamed "UNO"). Intravenously injected FAM-labeled UNO (FAM-UNO) homed to tumor and sentinel lymph node MEMs in different cancer models: 4T1 and MCF-7 breast carcinoma, B16F10 melanoma, WT-GBM glioma and MKN45-P gastric carcinoma. Fluorescence anisotropy assay showed that FAM-UNO interacts with recombinant CD206 when subjected to reducing conditions. Interestingly, the GSPGAK motif is present in all CD206-binding collagens. FAM-UNO was able to transport drug-loaded nanoparticles into MEMs, whereas particles without the peptide were not taken up by MEMs. In ex vivo organ imaging, FAM-UNO showed significantly higher accumulation in sentinel lymph nodes than a control peptide. This study suggests applications for UNO peptide in diagnostic imaging and therapeutic targeting of MEMs in solid tumors.

Indexed as

Drug Delivery SystemsAnimalsFemaleLectins, C-TypeMacrophagesMammary Neoplasms, ExperimentalMannose-Binding LectinsMannose ReceptorMiceMice, Inbred BALB CNeoplasm TransplantationPeptidesReceptors, Cell SurfaceRecombinant ProteinsLectins, C-TypeMannose-Binding LectinsMannose ReceptorPeptidesReceptors, Cell SurfaceRecombinant Proteins

Identifiers

PMID29116108
PMCPMC5676682
OpenAlexW2766886140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.